We are pleased to announce that CCSA has been contracted to support The Biomarkers Consortium’s observational clinical study of High Definition Single Cell Analysis of blood and tissue biopsies inpatients with colorectal cancer undergoing hepatic metastasectomy.

This project, if successful, will add an easily obtainable biomarker signature to the tools used by physicians treating patients with colorectal cancer, the second leading cause of cancer deaths in western countries.

For more information about The Biomarkers Consortium, please visit their website.


If you are interested in learning more about CCSA’s products and services, please contact us.


%d bloggers like this: